Athersys

Athersys Inc operates as a biotechnology company. The Company develops allogeneic stem cell products that focus on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions.In June 2007, Athersys completed a reverse merger with BTHC VI, which planned to change its name to Athersys. In the transaction, BTHC sold 13 million shares for $5 each raising $65 million. BTHC VI changed its name to Athersys in September 2007.In May 2004, Athersys had entered into a CRADA with the NIH to develop and apply stem cell technology for the treatment of cardiovascular disease. Athersys, in conjunction with the National Heart, Lung, and Blood Institute would apply Athersys' MAPC and genomics technologies to increase the understanding of basic stem cell biology, as well as to develop specific therapies for certain cardiovascular diseases.In December 2002, Athersys had acquired exclusive rights to an adult stem cell technology discovered by Dr